Results 81 to 90 of about 219,068 (308)
Advanced Science, EarlyView.Hepatocellular carcinoma (HCC)‐derived extracellular vesicles (EVs) enrich the metabolic enzyme ATP‐citrate lyase (ACLY). EV‐transferred ACLY enhances palmitate biosynthesis, increases the S‐palmitoylation and stability of multiple immune checkpoint proteins, augments the cellular immunosuppressive activity, and ultimately accelerates the malignant ...
Zhijun Liu +11 more
wiley +1 more source
Cancer Management and Research, 2020 Khaled Abouelezz,1 Dipen Khanapara,1 Gaber El-Saber Batiha,2 Esraa A Ahmed,3,4 Helal F Hetta1,5 1Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH, USA; 2Department of Pharmacology and Therapeutics, Faculty of ...
Abouelezz K +4 more
doaj
Advanced Science, EarlyView.This study identifies ARID3A as a key immunosuppressive transcription factor in TNBC. Its inhibition activates the type I IFN pathway, boosting CD8+ T cell infiltration and sensitizing tumors to anti‐PD‐1. The FDA‐approved migraine drug Rimegepant targets ARID3A, enhances immunotherapy efficacy in preclinical models, and establishes a druggable axis to
Teng Zhou +12 more
wiley +1 more source
Nine months to progression using fourth-line liposomally encapsulated paclitaxel against hepatocellular carcinoma [PDF]
, 2008 Background: Hepatocellular carcinoma (HCC) is the third most common cause of cancer deaths. Difficulties to diagnose HCC at early stages remain the major obstacle to curative (surgical) therapy. Therapy in advanced stages has to be considered palliative.
Forstpointner, Roswitha +6 more
core +1 more source
Vorinostat Potentiates Chemoimmunotherapy in Immune‐Enriched Pancreatic Cancer
Advanced Science, EarlyView.Immune‐enriched pancreatic cancer does not confer a significant survival advantage. SAHA sensitizes these “hot” tumors to chemoimmunotherapy by disrupting a FASN/PARP9‐driven “metabolic trap” and enhancing CD8+ T cell function. A CD8high/FASNhigh/PARP9high signature identifies patients who are most likely to benefit from the “gemcitabine‐nivolumab‐SAHA”
Chen Chen +13 more
wiley +1 more source
Circulating miR-210 and miR-1246 as potential biomarkers for differentiating hepatocellular carcinoma from metastatic tumors in the liver [PDF]
Journal of Medical Biochemistry, 2019 Background: To date few reports have pointed out the role of circulating miRNAs in discriminating metastatic liver tumors from primary hepatocellular (HCC) tumors. Such discrimination will have significant therapeutic and prognostic implications.
Ahmed Emad K. +3 more
doaj
Leveraging Artificial Intelligence and Large Language Models for Cancer Immunotherapy
Advanced Science, EarlyView.Cancer immunotherapy faces challenges in predicting treatment responses and understanding resistance mechanisms. Artificial intelligence (AI) and machine learning (ML) offer powerful solutions for cancer immunotherapy in patient stratification, biomarker discovery, treatment strategy optimization, and foundation model development.
Xinchao Wu +4 more
wiley +1 more source
Journal of Hepatocellular Carcinoma, 2021 Francesca Fornari,1,2 Catia Giovannini,1,3 Fabio Piscaglia,4,5 Laura Gramantieri4 1Centre for Applied Biomedical Research - CRBA, University of Bologna, St.
Fornari F +3 more
doaj
Advanced Science, EarlyView.This study establishes [68Ga]Ga‐DOTA‐AP9 as a first‐in‐human CD147‐targeted PET tracer with favorable safety and specific tumor uptake. Tracer accumulation correlates with CD147 expression in patients, enabling noninvasive quantification of CD147‐positive malignancies.
Xiaokun Ma +10 more
wiley +1 more source